Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cameron CE marks subcutaneous implantable defibrillator

This article was originally published in Clinica

Executive Summary

Cameron Health has CE marked its subcutaneous implantable defibrillator (S-ICD) device, a minimally-invasive system for use in patients at risk of sudden cardiac arrest. The system is entirely subcutaneous, with no leads in or on the heart, and imaging is not required to aid its placement, San Clemente, California-based Cameron claims. Surgical placement and presence of ICD leads within patients' hearts are associated with a significant proportion of the complications seen with the devices. Market launch in selected countries is due to begin this summer.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel